Royalty Report: Medical, Device, Delivery – Collection: 28235

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Medical
  • Device
  • Delivery
  • Respiratory
  • Therapeutic
  • cardiac
  • Drugs
  • Disease
  • Biotechnology
  • Fibrosis
  • Viral Infection
  • Surgical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28235

License Grant
The Amendment expands the scope of the Licensee's license from the Licensor. Under the Cross-License Amendment, the Licensee will continue to develop the pulse program in the field of cardiopulmonary disease.
License Property
The Licensor manufactures and markets pharmaceutical drugs and devices.

INOpulse is based on the Company’s proprietary pulsatile nitric oxide delivery device. The Company is currently developing two product candidates under its INOpulse program one for the treatment of pulmonary arterial hypertension, or PAH, for which the Company intends to commence Phase 3 clinical trials in the second half of 2015, and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease, or PH COPD, which is in Phase 2 development.

The INOpulse device is designed to be portable for use by ambulatory patients on a daily basis inside or outside their homes. The device is programmed to automatically adjust based on a patient’s breathing pattern to deliver a constant and appropriate dose of the inhaled nitric oxide over time, independent of the patient’s activity level, thus ensuring more consistent dosing in the alveoli of the lungs. In addition, we have developed a proprietary triple-lumen nasal cannula which enables more accurate delivery of the dose to the patient. The INOpulse device is also compatible with many long-term oxygen therapy systems that operate via a nasal cannula.

Field of Use
The Licensee will develop its Licensor pulse program for the treatment of three additional cardiopulmonary diseases chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary hypertension associated with sarcoidosis and pulmonary hypertension associated with pulmonary edema from high altitude sickness.

IPSCIO Record ID: 49323

License Grant
The parties wish to amend certain provisions of the Supply Agreement to, among other things, change the pricing terms; and the parties wish to amend certain provisions of the License Agreement to, among other things, add royalty terms, as additional consideration for the Products to be supplied under the Supply Agreement.
License Property
INOpulse is based on the Company’s proprietary pulsatile nitric oxide delivery device and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease, or PH COPD.  The INOpulse device is designed to be portable for use by ambulatory patients on a daily basis inside or outside their homes. The device is programmed to automatically adjust based on a patient’s breathing pattern to deliver a constant and appropriate dose of the inhaled nitric oxide over time, independent of the patient’s activity level, thus ensuring more consistent dosing in the alveoli of the lungs.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 263060

License Grant
In this Agreement, the Licensee expanded the scope of the license agreement with the Licensor, who prior to 2015 was Parent of Licensee, for rights to develop and commercialize pulsed nitric oxide for idiopathic pulmonary fibrosis to include patients with Pulmonary Fibrosis (PH-PF).
License Property
The Licensor manufactures and markets pharmaceutical drugs and devices, based on proprietary pulsatile nitric oxide delivery.

INOpulse program is an extension of the technology used in hospitals to deliver continuous-flow inhaled nitric oxide.

Field of Use
The clinical-stage therapeutics company focused on developing innovative products that address significant unmet medical needs in the treatment of cardiopulmonary diseases,  expanded the scope of the license from PH-IPF to PH in patients with Pulmonary Fibrosis (PH-PF), which includes idiopathic interstitial pneumonias, chronic hypersensitivity pneumonitis, occupational and environmental lung disease, with a royalty on net sales of any commercial products for PH-PF.  Pulmonary fibrosis is a lung disease that occurs when lung tissue becomes damaged and scarred.

IPSCIO Record ID: 376522

License Grant
The parties collaborated to advance the clinical development of high concentration Nitric oxide for the treatment of Nontuberculous Mycobacteria, or NTM pulmonary disease with Licensor providing grant money to be allocated to the ongoing LungFit® GO NTM pilot study.
License Property
Nitric oxide (“NO”) generator and delivery system (the “LungFit® system”) is capable of generating NO from ambient air. The LungFit® platform can generate NO up to 400 parts per million (“ppm”) for delivery to a patient’s lungs directly or via a ventilator. LungFit® can deliver NO either continuously or for a fixed amount of time at various flow rates and has the ability to either titrate dose on demand or maintain a constant dose. LungFit® can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections via delivery through a breathing mask or similar apparatus.
Field of Use
Field of use is for the treatment of Nontuberculous Mycobacteria, or NTM pulmonary disease.

Nontuberculous mycobacteria, also known as environmental mycobacteria, atypical mycobacteria and mycobacteria other than tuberculosis, are mycobacteria which do not cause tuberculosis or leprosy. NTM do cause pulmonary diseases that resemble tuberculosis. Nontuberculous mycobacterial (NTM) lung disease is a serious infection caused by bacteria that are common in the environment and can cause lung damage.

IPSCIO Record ID: 27221

License Grant
In 1998, the Company entered into a cooperative drug discovery agreement to identify and develop an antisense therapy as a potential treatment for pulmonary hypertension.
License Property
Pulmonary hypertension (PH or PHT) is an increase in blood pressure in the pulmonary artery, pulmonary vein, or pulmonary capillaries, together known as the lung vasculature, leading to shortness of breath, dizziness, fainting, and other symptoms, all of which are exacerbated by exertion. Pulmonary hypertension can be a severe disease with a markedly decreased exercise tolerance and heart failure.
Field of Use
The Field of Use apply to the medical industry.

IPSCIO Record ID: 256986

License Grant
The Company grants an exclusive license to an undisclosed Licensee for the commercialization of the GeNOvent for the treatment of persistent pulmonary hypertension of the newborn (PPHN) and future related indications at concentrations of <80 ppm in the hospital setting in the United States and another country.
License Property
GeNOvent is a novel cylinder free ventilator compatible nitric oxide (NO) generator and phasic-flow delivery system.

GeNOvent is a cylinder free, phasic flow nitric oxide delivery system and has been designated as a medical device by the US Food and Drug Administration (FDA). The device can generate NO on demand for delivery to the lungs at concentrations ranging from 1 part per million (ppm) to 80 ppm. A disposable smart filter is used to remove nitrogen dioxide (NO2), a toxic gas. The elimination of the need for large, high-pressure cylinders for NO is a significant advantage in the hospital setting by greatly reducing inventory and storage requirements, and improving overall safety with the elimination of NO2 purging steps, among other benefits.

The Licensor is a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension.

Nitric oxide (NO) is a crucially important molecule proven to play a critical role in a broad array of biological functions. Inhaled nitric oxide is currently approved for treating term and near-term neonates with Persistent Pulmonary Hypertension of the Newborn (PPHN) in the United States of America and most major markets. In Europe, Japan and Australia, inhaled NO is approved to treat PPHN as well as pulmonary hypertension during the peri-operative cardiac surgery period in neonates, children, and adults. In the airways, NO is believed to play a key role in the innate immune system at concentrations of approximately 200 ppm. In vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, both gram-positive and gram-negative, but also against other diverse organisms including mycobacteria, fungi, yeast and parasites, and has the potential to eliminate their multi-drug resistant strains.

Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening condition secondary to failure of normal circulatory transition at birth. It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased pulmonary blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1000 live births (0.4–6.8/1000 live births) with mortality rate ranging between 4–33%. This syndrome complicates the course of about 10% of infants with respiratory failure and remains a source of considerable morbidity and mortality. NO gas is a pulmonary vasodilator and is approved in dozens of countries to improve oxygenation and reduce the need for extracorporeal membrane oxygenation (ECMO) in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilator support and other appropriate agents.

Field of Use
This agreement pertains to the medical device industry.

IPSCIO Record ID: 857

License Grant
Licensor hereby grants to Licensee a license under the Licensor's IP to research, develop, use, import, make, have made, sell, and offer for sale Licensee Products in the Field in the Territory.

The Channel Agreement grants the Licensee a worldwide License to use specified patents and other intellectual property of the Licensor in connection with the research, development, use, importing, manufacture, sale, and offer for sale of products involving the production of PGIS (prostacylin synthase) through the use of an in vivo conditionally regulated embedded controllable bioreactor for the treatment of Pulmonary arterial hypertension (PAH)  in humans.

Licensee may not subLicense the rights described without Licensor's written consent.

License Property
Licensor has expertise in and owns or controls proprietary technology relating to the design and production of DNA vectors or their in vivo expression or the control of expression, as well as control over cell function.

The synthetic biologic product candidate is intended to treat PAH, a serious life-threatening lung disease. This product is designed to deliver DNA that encodes a therapeutic protein called prostacyclin synthase (PGIS) locally to the pulmonary arteries of PAH patients via a single procedure, and, via an oral daily pill, control the long-term local expression of such therapeutic protein.

Field of Use
The field of use include the production of prostaglandin synthase (PGIS) through the use of an in vivo conditionally regulated embedded controllable bioreactor for the treatment of PAH in humans.

Pulmonary arterial hypertension (PAH) is high blood pressure in the arteries of your lungs. It’s a serious condition that can make it difficult for blood to flow through your lungs. This can force your heart to work harder than normal.

The Licensee intends to use the Licensor's technology directed towards the production of PGIS, through the use of in vivo conditionally regulated embedded controllable bioreactors for the treatment of PAH.

IPSCIO Record ID: 353499

License Grant
Under the terms of the Settlement Agreement, the Licensee retains United States and China commercialization rights to LungFit® PH from United Kingdom Licensor.
License Property
LungFit® PH is an NO generator and delivery system (the LungFit™ system) that is capable of generating NO from ambient air. The LungFit™ system can generate NO up to 400 parts per million (ppm) for delivery to a patient’s lungs directly or via a ventilator. The LungFit™ system can deliver NO either continuously or for a fixed amount of time at various flow rates and has the ability to either titrate dose on demand or maintain a constant dose.
Field of Use
Field of use is for the treatment of persistent pulmonary hypertension of the newborn (PPHN), severe acute respiratory syndrome coronavirus 2 (“SARS CoV-2”)/acute viral pneumonia (“AVP”), bronchiolitis (BRO) and nontuberculous mycobacteria (“NTM”) lung infection.

Licensee current areas of focus with LungFit® are persistent pulmonary hypertension of the newborn (“PPHN”), acute viral pneumonia (“AVP”) including COVID-19, bronchiolitis (“BRO”) and nontuberculous mycobacteria (“NTM”) lung infection.

IPSCIO Record ID: 213206

License Grant
The Irish Licensor grants the Licensee a worldwide license for the use of Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease.
License Property
Trelegy Ellipta is a prescription medication used to treat chronic obstructive pulmonary disease (COPD), a group of diseases that includes chronic bronchitis and emphysema.

COPD is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 268269

License Grant
Licensor will manufacture and supply the Implantable System for Remodulin, and Licensee will manufacture and supply Remodulin for use in the system. Each party will perform certain additional activities to support the commercialization of the Implantable System for Remodulin.
License Property
The system incorporates a proprietary Licensor intravascular infusion catheter with Medtronic’s SynchroMed® II implantable infusion pump and related infusion system components (together referred to as the Implantable System for Remodulin) in order to deliver Remodulin for the treatment of pulmonary arterial hypertension (PAH). We believe this technology has the potential to reduce many of the patient burdens and other complications associated with the use of external pumps to administer prostacyclin analogues.
Field of Use
The Parties wish to collaborate on the commercialization in the United States of the delivery of Remodulin® (treprostinil) injection drug to patients with pulmonary arterial hypertension using Medtronic implantable pumps, catheters, and programmers, and related Medtronic accessories.

IPSCIO Record ID: 388300

License Grant
Licensee entered into an Agreement with an undisclosed third party for a perpetual, exclusive, world-wide license to certain intellectual property related to the Oxygen Assist Module for the delivery of non-invasive ventilatory support.
License Property
Oxygen Assist Module is designed to automatically maintain SPO2 levels within a specified range for a defined period of time. The device solution is focused on High Velocity Nasal Insufflation (“HVNI”, or “High Velocity Therapy”), which delivers non-invasive ventilatory support to patients by providing heated, humidified, oxygenated air at high velocities through a small-bore nasal interface, and on closed loop control systems.

This license is for the delivery of non-invasive ventilatory support relating to the Oxygen Assist Module focused on at home patient monitoring.

Field of Use
High Velocity Therapy is an advanced form of high flow therapy that is differentiated due to its ability to deliver breathing gases, including oxygen, at a high velocity, for the treatment of spontaneously breathing patients with either Type 1 hypoxic respiratory distress, like that experienced by patients with pneumonia or COVID-19, or Type 2 hypercapnic respiratory distress, like that experienced by patients with COPD. Licensee's Precision Flow systems, which use High Velocity Therapy technology, are clinically validated alternatives to, and address many limitations of, the current standard of care for the treatment of respiratory distress in a hospital setting.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.